Last reviewed · How we verify
TR701 FA
At a glance
| Generic name | TR701 FA |
|---|---|
| Also known as | Tedizolid |
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Nausea
- diarrhea
- cellulitis
- abscess
- vomiting
- dizziness
- headache
- chills
- constipation
- somnolence
Key clinical trials
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) (PHASE1)
- A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) (PHASE1)
- Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg (PHASE1)
- Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) (PHASE3)
- Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients (PHASE1)
- A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects (PHASE1)
- A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TR701 FA CI brief — competitive landscape report
- TR701 FA updates RSS · CI watch RSS
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI